Latest news for Banca Mediolanum (OTC:BNCDY) Stock

Banca Mediolanum is an Italy-based company which provides banking and financial services. It operates with various segments namely Lending which includes Retail and Commercial Banking, Treasury activities which has trading and sales, Asset Management and Retail Brokerage. The company offers current accounts, mortgages and loan products; credit, debit, and rechargeable cards and investment products. Geographically, it operates the market of Italy, Spain, and Germany of which Italy accounts for a larger share of revenue.

News

Intraday Update

Markets

Movers

Trading Ideas

AAXN

ADUS

AIQUF

ALLE

ALNY

AMED

AMTB

AMWD

ANCUF

APPF

ARWR

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

BANX

BF-A

BF-B

BLDR

BLMN

BMCH

BNCDY

BNTGF

BRLXF

BTBIF

BURL

CACI

CARE

CATO

CBFV

CBNK

CBRE

CCXI

CDAY

CLLXF

CMTL

CNNE

CNSWF

COFS

COLL

CRHCF

CSLLY

CTAC

CVNA

DOOO

DOOR

DSDVF

DSDVY

DSGX

DXCM

EBSB

EPAM

EPIX

ESNT

EVER

EVRI

FBHS

FISI

FIVN

FLXN

FSBW

FSUGY

GAIN

GEAGY

GMED

GNGBY

GNRC

GWRE

GWRS

GZTGF

HCCI

HNGR

Stocks That Hit 52-Week Highs On Tuesday

BANCA MEDIOLANUM UNSP/ADR by Banca Mediolanum SPA

Banca Mediolanum

On Tuesday, General Motors Company&nbsp;(NYSE:&nbsp;GM) reported a fiscal second-quarter 2024 sales growth of 7.2% year-on-year to $47.97 billion, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n39901339/gm-releases-2024-second-quarter-results-and-raises-full-year-guidance" rel="noreferrer noopener">analyst&nbsp;consensus estimate of $45.30 billion</a>.
The adjusted EPS of $3.06 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $2.72</a>.
General Motors&#8217; market share reached 8.4% for the quarter, compared to&nbsp;9.1% a year ago. In the U.S., the share changed to 16.6%, up from 16.4%. Its share in China reached 6.4%, down from 8.6% a year earlier.
Adjusted EBIT for the quarter improved by 37.2% to $4.40 billion, with an adjusted EBIT margin of 9.3%, up by 210 bps. Net income margin was 6.1% versus 5.7% a year ago.
The company held $30.83 billion in cash and equivalents as of June 30, 2024. The adjusted automotive free cash flow was $5.3 billion.
General Motors CFO Paul Jacobson <a target="_blank" href="https://www.cnbc.com/2024/07/23/general-motors-gm-earnings-q2-2024.html" rel="noreferrer noopener">told CNBC</a> that the automaker expects to see some seasonally higher commodity costs and some pricing headwinds it assumed in the second half of the year.
General Motors told CNBC that it is&nbsp;pausing&nbsp;production of its Cruise Origin autonomous vehicle, leading to a $600 million special charge in the second quarter. It also shared its plans for a joint venture in China with SAIC,&nbsp;including a $104 million loss in equity income during the second quarter.
Jacobson told CNBC that General Motors&#8217; North American operations,&nbsp;driven by truck sales for the company&#8217;s second-quarter beat and guidance raise. At the same time, it failed to return to profitability in China.
General Motors&#8217; electric vehicle deliveries during the quarter grew by 40% year over year to 21,930 units. However, EVs accounted for only 3.2% of its second-quarter U.S. sales.
Jacobson reconfirmed to CNBC that General Motors expects its EVs to be profitable on a production or contribution-margin basis once it reaches 200,000 units by the fourth quarter.
FY24 Guidance raise: General Motors projects adjusted EPS of $9.50 &#8211; $10.50 (<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38379260/general-motors-q1-earnings-surprise-north-america-growth-rising-profit-margin-and-annual-guidance-b" rel="noreferrer noopener">prior $9.00 – $10.00</a>) versus&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $9.72</a>.&nbsp;
The company projects adjusted automotive free cash flow of $9.5 billion—$11.5 billion (prior $8.5 billion—$10.5 billion) and reiterated capital spending of $10.5 billion—$11.5&nbsp;billion.
Despite slower-than-expected adoption, General Motors continues to target production and vehicle wholesales&nbsp;of 200,000 and 250,000 all-electric vehicles&nbsp;in North America.
Price Action: GM shares were trading higher by 2.70% at $50.90 premarket at the last check on Tuesday.
Photo via Shutterstock

Earnings

Guidance

Topics

Media

General Motor's Q2 Earnings: Revenue Beat, Hikes Annual Outlook But Faces Challenges In EVs And China

Xylo Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XYLO#NASDAQ">XYLO</a>) ("Xylo", and the "Company"), a technology-based company engaged in advanced innovative technologies, announced today that Charging Robotics, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CHEV#OTC">CHEV</a>) ("Charging Robotics"), an innovator of wireless charging solutions held 67% by Xylo, received its first commercial order for the deployment of its wireless charging system designed for automatic parking facilities. This order comes from Parking Design Ltd. ("Parking Design"), a leading innovator in developing and designing parking solutions. This collaboration, announced on June 27, 2024, marks important progress in the evolution of automated parking and electric vehicle (EV) charging technologies.
The purchase order is for an initial batch of 12 systems, capable of wireless charging. The system enables several EVs to be charged at the same time, significantly improving the efficiency and convenience of automatic parking facilities.

Contracts

CHEV

XYLO

Xylo Technologies' Charging Robotics Lands Commercial Order For EV Wireless Charging Systems In Automatic Car Parks From Parking Design Ltd.

Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) and Macquarie AirFinance announced today that the lessor has made its first direct order for Boeing airplanes. The purchase of 20 737-8s doubles Macquarie AirFinance's existing 737-8 order book, which it acquired from ALAFCO Aviation Lease and Finance Co. in 2023.

Global

Macquarie AirFinance Places First Boeing Order With Purchase Of 20 737-8s MAX Jets

Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) shares are trading higher following better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39902092/coca-cola-reports-second-quarter-2024-results-and-raises-full-year-guidance" rel="noreferrer noopener">second-quarter FY24 earnings and a raised outlook.</a>
The company reported second-quarter FY24 sales growth of 3% year-on-year to $12.4 billion, beating the analyst consensus estimate of $11.753 billion.
Revenue performance included a 6% climb in concentrate sales and a 9% growth in price/mix. Unit case volume grew 2% in the quarter. Organic revenues increased 15%.
Coca-Cola&#8217;s organic revenue in Europe, Middle East and Africa jumped 30% in the second quarter, while in North America, it increased 10%.
Gross profit rose 7% to $7.551 billion with a profit margin of 61.1%. The operating margin expanded 120 basis points to 21.3%, while the comparable operating margin gained 120 basis points to 32.8%.&nbsp;
Operating income for the quarter increased 10% to $2.63 billion. Adjusted EPS of $0.84 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus estimate of $0.81.</a>
Operating cash flow generated for six months was $4.1 billion, a decrease of $516 million from the prior year. Free cash flow totaled $3.3 billion. KO held $17.39 billion in cash and equivalents as of June 28.
Outlook: Coca-Cola raised its FY24 organic revenue <a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38519595/coca-colas-bottom-line-bubbles-up-company-raises-fy24-revenue-projections" rel="noreferrer noopener">growth outlook from 8% &#8211; 9%</a> to 9% &#8211; 10%.
KO raised comparable currency neutral EPS growth outlook from 11% &#8211; 13% to 13% &#8211; 15%.
The company raised comparable EPS (non-GAAP) growth guidance from 4% &#8211; 5% to <a href="https://www.benzinga.com/calendars/guidance">5% &#8211; 6% versus $2.69 in 2023.</a>
Coca-Cola still expects to generate free cash flow (non-GAAP) of approximately $9.2 billion through cash flow from operations of approximately $11.4 billion, less capital expenditures of approximately $2.2 billion.
Price Action: KO shares are trading higher by 1.65% at $65.84 in premarket at the last check Tuesday.
Image: Shutterstock/ Ravi_Sharma1030

Equities

General

Coca-Cola's Sweet Surge: Q2 Earnings Soar, Raises 2024 Forecasts

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Overweight rating and announces Price Target of $13.

Price Target

Initiation

Analyst Ratings

ALMS

Cantor Fitzgerald Initiates Coverage On Alumis with Overweight Rating, Announces Price Target of $13

Ormat Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORA#NYSE">ORA</a>), a leading renewable energy company, today announced the signing of a 15-year Resource Adequacy Purchase and Sale Agreement (RA Agreement) with the City of Riverside for the 80MW/320MWh Shirk Battery Energy Storage System (BESS) located in Visalia, California.

Ormat Secures 15-Year Resource Adequacy Purchase And Sale Agreement With The City Of Riverside For The 80MW/320MWh Shirk Battery Energy Storage System Located In Visalia, California.

Barclays analyst Steve Valiquette maintains Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) with a Underweight and lowers the price target from $11 to $7.

Barclays Maintains Underweight on Walgreens Boots Alliance, Lowers Price Target to $7

–&nbsp; Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis&nbsp;–
GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4217125-1&amp;h=2601758121&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc.">Precigen, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4217125-1&amp;h=1226164084&amp;u=https%3A%2F%2Finvestors.precigen.com%2Fnews-releases%2Fnews-release-details%2Fprecigen-announces-groundbreaking-pivotal-study-data-prgn-2012&amp;a=PRGN-2012+AdenoVerse+gene+therapy+in+recurrent+respiratory+papillomatosis+(RRP)">PRGN-2012 AdenoVerse gene therapy in recurrent respiratory papillomatosis (RRP)</a>. Mr. Tennant will report to Precigen's President and CEO, Helen Sabzevari, PhD, and will join Precigen's executive leadership team.

Biotech

PGEN

Precigen To Spearhead First Potential Gene Therapy Launch

<ul>
<li>Approximately 40% of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp &nbsp;</li>
<li>Once-daily ZORYVE foam significantly improved both scalp and body psoriasis in a Phase 2b and a pivotal Phase 3 trial</li>
<li>Data also show rapid reduction in scalp itch as soon as 24 hours after first application</li>
<li>ZORYVE foam demonstrated a favorable safety and tolerability profile</li>
</ul>
WESTLAKE VILLAGE, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=1rc5uloepaLRUEBzCsDsd6-eN0q4k9US8wImyFHHqpkReNvF5mkw3Cm56x-Wdh0K-4fg8EujN_tYr7Hg4pQvB_xMv-EfX0A0sfNKG7Xw7_0=">Arcutis Biotherapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) foam 0.3%, a once-daily, next generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis.

ARQT

Arcutis Submits Supplemental NDA For ZORYVE Foam To The FDA For The Treatment Of Scalp And Body Psoriasis In Adults And Adolescents Ages 12 And Over

Barclays analyst Jason Goldberg maintains Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) with a Equal-Weight and raises the price target from $43 to $47.

Barclays Maintains Equal-Weight on Truist Finl, Raises Price Target to $47

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is said to be planning to integrate its A18 chip into its upcoming entry-level iPhones and iPads in order to make them capable of running <a href="https://www.benzinga.com/topic/apple-intelligence">Apple Intelligence</a>, the company's suite of AI features.
What Happened: According to known <a href="https://weibo.com/5673255066/OoxQuAnxl?pagetype=profilefeed">tipster</a> Ice Universe, Cupertino is keen on extending its Apple Intelligence features to its entry-level devices. This news follows the speculations surrounding the specifications of the upcoming fourth-generation iPhone SE.
The tipster disclosed that the new iPhone SE would likely be powered by the A18 chip, the same chip anticipated to power the entire iPhone 16 lineup.
Traditionally, the iPhone SE has always utilized the chip from the latest iPhones. However, this year saw the introduction of Apple Intelligence, and <a href="https://www.benzinga.com/news/24/06/39267314/will-your-iphone-support-new-apple-intelligence-features-heres-what-you-need-to-know">only iPhones equipped with the A17 Pro chip</a> received the new AI features with iOS 18.
This could explain why all new iPhone 16 models will receive the A18 chip, to ensure access to the latest features.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Apple&#8217;s decision to use the A18 chip in the new iPhone SE suggests that the company is using AI features as a selling point. Rumors also suggest that the new HomePod with a touchscreen might be powered by the A18 chip, indicating that Apple may update the entry-level iPad and iPad mini with its latest chip.
See Also: <a href="https://www.benzinga.com/news/24/07/39835993/apple-denies-using-youtube-videos-to-train-its-ai-features-after-report-claims-tim-cooks-company-use">Apple Denies Using YouTube Videos To Train Its AI Features After Report Claims Tim Cook&#8217;s Company Used Creators&#8217; Content Without Consent</a>
Why It Matters: Apple&#8217;s AI-powered features, collectively known as <a href="https://www.benzinga.com/news/24/06/39256948/tim-cook-announces-apple-intelligence-for-iphones-calls-it-next-big-step-tremendously-excited">Apple Intelligence</a>, were first unveiled at the Worldwide Developers Conference in June.
Apple&#8217;s top executives clarified that the decision to limit Apple Intelligence features to the latest iPhone models was <a href="https://www.benzinga.com/news/24/06/39408910/limiting-apple-intelligence-features-not-a-tactic-to-boost-iphone-sales-say-top-executives-we-wouldv">not a tactic to boost iPhone sales</a>. If Apple does bring its AI feature set to entry-level iPhones, it would be the first time since the iPhone 14 that all the models run on the same chipset, instead of the entry-level models running a generation behind.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39881748/elon-musks-xai-flips-the-switch-on-100k-nvidia-h100-gpus-worth-up-to-4b-in-memphis-supercluster-most">Elon Musk&#8217;s xAI Flips The Switch On 100K Nvidia H100 GPUs Worth Up To $4B In Memphis Supercluster: &#8216;Most Powerful AI Training Cluster In The World&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Apple

Tech

AAPL

Apple Plans A18 Chip Integration To Bring AI Features To iPhone 16, Its Entry-Level Variants And iPads: Report

TransUnion Announces Partnership With SafeGuard Privacy To Streamline Marketers' Compliance Vetting For Third-Party Audience Vendors; Aims To Enhance First-Party Data Assets Amid Evolving Market

Peacock and its parent company, Comcast Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), are gearing up for a pivotal moment with the upcoming 2024 Olympics in Paris.
Pacock's president, Kelly Campbell, is spearheading efforts with two dedicated task forces to attract viewers during the Games and ensure they remain engaged afterward.
With the opening ceremonies just days away, Campbell and her superiors believe the Olympics will significantly boost Peacock's position in the competitive streaming landscape against giants like Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) and Walt Disney Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) Disney+, <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-07-22/comcast-bets-on-paris-olympics-to-make-peacock-a-must-have?srnd=phx-industries-entertainment&amp;sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a> reports.
"This is going to be a defining moment for Peacock," Campbell said in a recent interview. Over a 19-day period, Peacock will exclusively stream every Olympic event for U.S. viewers, offering thousands of hours of live and on-demand content, including a high-tech morning recap narrated by an AI-synthesized version of Al Michaels' voice.
For NBCUniversal, Comcast's media division, the stakes are high. The division, which owns several cable networks like Bravo, E!, and USA, faces significant pressure as viewers continue to shift from traditional TV bundles to streaming services, Bloomberg writes.
Comcast has invested billions into Peacock, yet it still trails behind competitors like Netflix and Walt Disney.
Comcast had intended to use the 2020 Tokyo Olympics to launch Peacock, but the pandemic delayed the launch. Despite the setbacks, the service launched in July 2020.
Related Read: <a target="_blank" href="https://www.benzinga.com/m-a/24/07/39838603/warner-bros-discovery-shares-are-surging-thursday-as-ceo-considers-asset-sales-spinoff" rel="noreferrer noopener">Warner Bros Discovery CEO Considers Asset Sales, Spinoff</a>
Unlike other streaming services, Peacock started as a free, ad-supported platform with optional paid tiers. Initially, it struggled to attract subscribers without the Olympic boost, but the pandemic created a captive audience that drove growth.
In a strategic meeting in 2021, Comcast CEO Brian Roberts approved increased investments in Peacock, including more original content, movies, and sports.
The platform has since reclaimed popular series and movies and released hit originals like "Poker Face" and "The Best Man: The Final Chapters." Peacock has also secured exclusive rights to major sports events, including NBA and NFL games, bolstering its appeal.
Peacock now costs $7.99 a month following price increases to fund new programming. Despite high churn rates, the service continues to attract new subscribers, partly due to its strategic releases during major sporting events.
The upcoming Olympics will feature promotions for new shows like "Fight Night" and "The Day of the Jackal," leveraging the excitement of the Games to retain viewers.
With 34 million subscribers as of March, Peacock outperforms some rivals in U.S. viewership.
Comcast stock has lost more than 5% in the last 12 months. Investors can gain exposure to the stock via&nbsp;IShares U.S. Telecommunications ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IYZ#BATS">IYZ</a>) and Vanguard Communication Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOX#NYSE">VOX</a>).
Price Action: CMCSA shares were trading lower by 3.04% at $38.93 premarket at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/06/39496372/comcasts-universal-plans-new-uk-theme-park-eyes-massive-job-creation-report" target="_blank" rel="noreferrer noopener">Comcast's Universal Plans New UK Theme Park, Eyes Massive Job Creation: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by rarrarorro on Shutterstock

CMCSA

iShares Dow Jones US Telecommunications Sector Index Fund

NFLX

Comcast's Paris Olympics Bet For Boosting Peacock's Viewership: Report

Ozuriftamab vedotin, the Company's conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in treatment-refractory patients with squamous cell carcinoma of the head and neck (SCCHN) in its Phase 2 clinical trial &nbsp;
The Company is on track to meet with the FDA for guidance on a potentially registrational trial in 2H 2024
SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ozuriftamab vedotin, the Company's conditionally and reversibly active ROR2 antibody drug conjugate directed for the treatment of patients with recurrent or metastatic SCCHN with disease progression on or after platinum-based chemotherapy and anti-PD-1/L1 antibody therapy.

BCAB

BioAtla Granted FDA Fast Track Designation For Ozuriftamab Vedotin For Treatment Of Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck

Market-Moving Exclusives

Exclusives

ADIL

EXCLUSIVE: Milestone Scientific Tells Benzinga 'This new price assignment applies to two Medicare regions: Jurisdiction L (JL) and Jurisdiction H (JH)'

Bionano Genomics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>), today announced&nbsp;the&nbsp;publication of&nbsp;the first&nbsp;multi-site study&nbsp;in multiple myeloma&nbsp;(MM)&nbsp;comparing&nbsp;optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural&nbsp;variants&nbsp;(SVs).
Multiple myeloma is a type of blood cancer originating in the plasma cell, known as a plasma cell neoplasm (PCN), and though sensitive and accurate identification of genetic abnormalities in MM samples is critical for patient risk stratification, predication of response to therapy options, and understanding of pathogenesis, many genome analysis methodologies, including fluorescence in situ hybridization (FISH) and chromosomal microarray (CMA), are limited in their ability to detect complex gene rearrangements in PCN samples. Additionally, karyotype (KT) fails for PCNs at a higher rate than for leukemias because plasma cells are fragile and grow poorly in culture, leaving additional unmet need. Because OGM doesn't require culture, it may be well suited to fill this gap.

BNGO

Bionano Announces Publication Of First Multi-Site Study To Analyze The Utility Of OGM In Multiple Myeloma

Barclays analyst Christine Cho maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Equal-Weight and raises the price target from $16 to $19.

Barclays Maintains Equal-Weight on Sunrun, Raises Price Target to $19

MLSS

EXCLUSIVE: Milestone Scientific Tells Benzinga Co. Announces Medicare Price Assignment For The CompuFlo Epidural System In Texas, Pennsylvania, New Jersey, Colorado, Oklahoma, Louisiana, Arkansas, Mississippi, New Mexico, District Of Columbia, and Delawar

On Tuesday, Milestone Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#NYSE">MLSS</a>) announced that Novitas Solutions, Inc., a Jurisdictional Medicare Administrative Contractor (JMAC), has granted a Medicare Part B Physician payment rate for the company&#8217;s CompuFlo Epidural System under the American Medical Association&#8217;s (AMA) technology-specific Category III CPT code CPT0777T (real-time pressure-sensing epidural guidance system when used in conjunction with a primary ESI procedure).
This new price assignment applies to two Medicare regions:
<ul>
<li>Jurisdiction L (JL) includes Delaware, District of Columbia, Maryland, New Jersey, and Pennsylvania.</li>
<li>Jurisdiction H (JH) includes Arkansas, Colorado, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.</li>
</ul>
The pricing assignment by Novitas represents a significant step forward in Milestone Scientific&#8217;s strategy to ensure broad coverage and appropriate payment for the CompuFlo technology when deemed medically necessary and clinically appropriate for Medicare beneficiaries.
This decision follows the recently announced Medicare Jurisdiction N (JN) pricing assignment in Florida by First Coast Service Options Inc.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/07/39707524/exclusive-milestone-scientific-announces-favorable-medicare-pricing-for-compuflo-epidural-system-for" rel="noreferrer noopener">EXCLUSIVE: Milestone Scientific Announces Favorable Medicare Pricing For CompuFlo Epidural System For Back Pain Covering Florida</a>.
An estimated 3.0 million epidural steroid injection (ESI) procedures are performed yearly in these three jurisdictions (JL, JH, JN), representing approximately one-third of the total ESI procedures for treating chronic back pain in the United States.
Additionally, Medicare is expected to account for up to 40% of the clinical practice volume, representing an initial addressable market of approximately $250 million among Medicare patients in these three jurisdictions, the company said.
The CompuFlo Epidural System uses Milestone Scientific&#8217;s patented Dynamic Pressure Sensing technology, which provides real-time feedback to ensure accurate needle placement during epidural procedures. This technology is designed to reduce the morbidity, pain, and discomfort associated with traditional epidural techniques.
Price Action: MLSS stock is trading lower by 4.49% at $0.83 premarket at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39891711/anaptysbio-investigational-arthritis-drug-might-have-better-efficacy-profile-than-eli-lillys-anal" target="_blank" rel="noreferrer noopener">AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly&#8217;s: Analyst</a>.</li>
</ul>

Government

Health Care

EXCLUSIVE: Milestone Scientific Announces Medicare Price Assignment For CompuFlo Epidural System For Back Pain Covering Additional US States

With 7% interest rates or higher, housing markets across the country are still stagnant. But in certain markets around major east coast cities, buyers are snapping up homes. If you want to buy a home and can&#8217;t afford a property in the city, there&#8217;s still time to get into these markets before investors snap them up.&nbsp;
Don't Miss:
<ul>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a></li>
</ul>
Considering that the average <a href="https://www.zillow.com/home-values/44269/boston-ma/">home price in both Boston</a> and <a href="https://www.zillow.com/home-values/6181/new-york-ny/">NYC is over $750,000</a>, a home just two hours from a major city for $450,000 seems unbelievable. Unsurprisingly, according to a new report from Realtor.com, demand in the top 20 markets was 2.8 times the national level in June, as measured by views per property. America's hottest housing markets rose an average of 8.1% last year.
Hartford, CT, ranked as the country's hottest housing market this June, with an average home price of just $17,000 above <a href="https://fred.stlouisfed.org/series/MSPUS">the national average</a>. A home with a yard, a large kitchen, and multiple bedrooms and bathrooms in NYC could cost more than $1 million. In Hartford, only two hours from the city, you could get a comparable home for just $450,000.&nbsp;
In addition to Hartford, which came in at #1, Connecticut has four other cities in the top 20: New Haven-Milford, Worcester, Bridgeport-Stamford-Norwalk, and Norwich-New London.
Most other booming areas have one thing in common: proximity to major metropolitan areas with much better prices. Manchester, NH, coming in at #2, is just an hour from Boston. Its average home prices are higher than Hartford at $598,000, but still affordable compared to Boston. New Hampshire also has no state income or sales tax, giving both investors and residents more savings.&nbsp;
Trending: Rory McIlroy&#8217;s mansion in Florida is worth $22 million today, doubling from 2017 —<a href="https://benzinga.com/money/rory-mcilroys-florida-mansion-doubled-in-value"> here&#8217;s how to get started investing in real estate with just $100</a>
Rockford, IL, just 90 minutes outside Chicago, took the #3 spot with a median housing price of just $220,000. Rounding out the top five was Oshkosh-Neenah, WI, at #4, just 1.5 hours from Milwaukee or 40 minutes from Green Bay. Finally, Rochester, NY, in growing upstate NY, came in at #5. In Rochester, houses spend a median of 17 days on the market, 28 days less than the national average.&nbsp;
If you&#8217;re ready to buy, Benzinga can walk you through the <a href="https://www.benzinga.com/money/how-to-get-approved-for-a-mortgage">steps to get a mortgage</a>, or you can find the <a href="https://www.benzinga.com/money/best-mortgage-lenders">best online mortgage lenders</a>.
Here&#8217;s the full list of the top 20, with median list prices and average days on the market:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>City</td>
<td>Average List Price</td>
<td>Median Days on the Market</td>
</tr>
<tr>
<td>Hartford, CT</td>
<td>$450,000</td>
<td>17</td>
</tr>
<tr>
<td>Manchester, NH</td>
<td>$598,000</td>
<td>16</td>
</tr>
<tr>
<td>Rockford, IL</td>
<td>$220,000</td>
<td>19</td>
</tr>
<tr>
<td>Oshkosh, WI</td>
<td>$389,000</td>
<td>23</td>
</tr>
<tr>
<td>Rochester, NY</td>
<td>$300,000</td>
<td>17</td>
</tr>
<tr>
<td>Springfield, MA</td>
<td>$412,000</td>
<td>24</td>
</tr>
<tr>
<td>Akron, OH</td>
<td>$265,000</td>
<td>24</td>
</tr>
<tr>
<td>Guangzhou, OH</td>
<td>$255,000</td>
<td>22</td>
</tr>
<tr>
<td>Concord, NH</td>
<td>$600,000</td>
<td>26</td>
</tr>
<tr>
<td>Providence, RI</td>
<td>$599,000</td>
<td>23</td>
</tr>
<tr>
<td>Worcester, MA</td>
<td>$550,000</td>
<td>23</td>
</tr>
<tr>
<td>Bridgeport, CA</td>
<td>$960,000</td>
<td>25</td>
</tr>
<tr>
<td>Syracuse, NY</td>
<td>$350,000</td>
<td>28</td>
</tr>
<tr>
<td>Columbus, OH</td>
<td>$400,000</td>
<td>25</td>
</tr>
<tr>
<td>Reading, PA</td>
<td>$365,000</td>
<td>21</td>
</tr>
<tr>
<td>Erie, PA</td>
<td>$262,000</td>
<td>30</td>
</tr>
<tr>
<td>Lafayette, IN</td>
<td>$380,000</td>
<td>24</td>
</tr>
<tr>
<td>Norwich, CT</td>
<td>$550,000</td>
<td>30</td>
</tr>
<tr>
<td>Springfield, IL</td>
<td>$205,000</td>
<td>29</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
<li>Sun Belt's booming real estate market prepares for millions of new inhabitants —<a href="https://www.benzinga.com/money/integris"> Here&#8217;s how to find the region's best deals!</a></li>
</ul>

Real Estate

Exodus from NYC and Boston: How Connecticut's 'Bargain' $450K Homes Are Luring the Elite and Squeezing Out Locals

In a report released today, Adele Palama from UBS maintained a Buy rating on Banca Mediolanum SpA (BNMDF – Research Report), with a price target of...

UBS Keeps Their Buy Rating on Banca Mediolanum SpA (BNMDF)

In a report released on February 9, Filippo Prini from Kepler Capital maintained a Buy rating on Banca Mediolanum SpA (BNMDF – Research Report), wi...

Banca Mediolanum SpA (BNMDF) Gets a Buy from Kepler Capital

Banca Mediolanum S.p.A. goes ex dividend Monday

Banca Mediolanum SpA (BNMDF) Receives a Buy from UBS

Kepler Capital analyst Filippo Prini maintained a Buy rating on Banca Mediolanum SpA (BNMDF – Research Report) on May 10 and set a price target of ...

Kepler Capital  Sticks to Their Buy Rating for Banca Mediolanum SpA (BNMDF)

In a report released on May 10, Paola Sabbione from Barclays maintained a Buy rating on Banca Mediolanum SpA (BNMDF – Research Report), with a pric...

Barclays Keeps Their Buy Rating on Banca Mediolanum SpA (BNMDF)

Kepler Capital analyst Filippo Prini maintained a Buy rating on Banca Mediolanum SpA (BNMDF – Research Report) on June 6 and set a price target of ...

In a report released on June 24, Filippo Prini from Kepler Capital maintained a Buy rating on Banca Mediolanum SpA (BNMDF – Research Report), with ...

In a report released on July 5, Filippo Prini from Kepler Capital maintained a Buy rating on Banca Mediolanum SpA (BNMDF – Research Report), with a...

Banca Mediolanum SpA (BNMDF) Receives a Buy from Kepler Capital

In a report released today, Paola Sabbione from Barclays maintained a Buy rating on Banca Mediolanum SpA (BNMDF – Research Report). The company's s...

Barclays Reaffirms Their Buy Rating on Banca Mediolanum SpA (BNMDF)

BNMDF

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Banca Mediolanum

News

Latest news for Banca Mediolanum (OTC:BNCDY) Stock

Tuesday, November 26, 2019